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ABSTRACT
Methotrexate (MTX) is a folate-antagonist used in several
neoplastic and inflammatory diseases. Reports of pulmonary
complications in patients given low-dose MTX therapy are
increasing. Pulmonary toxicity from MTX has a variable fre-
quency and can present with different forms. Most often
MTX-induced pneumonia in patients affected by rheumatoid
arthritis (RA) is reported.
In this paper we describe a case of MTX-related pneumonitis
in a relatively young woman affected by Crohn's disease who
presented non-productive cough, fever and dyspnea on exer-
cise. Chest X-ray demonstrated bilateral interstitial infil-
trates and at computed tomography (CT) ground-glass opac-
ities appeared in both lungs. At spirometry an obstructive
defect was demonstrated. A rapid improvement of symptoms
and the regression of radiographic and spirometric alter-
ations was achieved through MTX withdrawal and the intro-
duction of corticosteroid therapy.
Keywords: Crohn’s disease, CT, methotrexate, pneumonitis,
spirometry.
RIASSUNTO 
Il metotrexate (MTX) è un antagonista dei folati che viene
utilizzato in molte malattie neoplastiche e infiammatorie.
Negli ultimi anni sono divenute più frequenti le segnalazioni
di complicanze polmonari in pazienti sottoposti a terapia con
basse dosi di metotrexate. Variabile è l’incidenza della tossi-
cità da metotrexate, che può manifestarsi in diverse forme.
Più spesso viene riportata una polmonite indotta da MTX in
pazienti affetti da artrite reumatoide (AR).
Qui si descrive il caso di una polmonite indotta da metotrexa-
te in una donna relativamente giovane affetta da morbo di
Crohn, che presentava tosse non produttiva, febbre e dispnea
da sforzo. La radiografia standard del torace mostrava infiltra-
ti interstiziali, mentre alla TAC erano evidenti opacità a vetro
smerigliato in entrambi i polmoni. La spirometria documenta-
va un difetto di tipo ostruttivo. 
Si otteneva un rapido miglioramento dei sintomi e la regres-
sione delle alterazioni radiologiche e funzionali respiratorie
con la sospensione del MTX e l’introduzione di una terapia
steroidea. 
Parole chiave: Metotrexate, morbo di Crohn, polmonite, spiro-
metria, TAC.  
INTRODUCTION
The rate of extra-intestinal manifestations in patients
with inflammatory bowel disease (IBD) ranges from
21 to 41% [1,2], increasing with the duration of
intestinal disease. The true prevalence of lung
involvement in IBD seems rather variable; in fact
Edwards et al. [3] in their review of 624 cases found
no case of pulmonary complication, whereas
Rogers et al. [4] report an incidence of 0.4%.
Respiratory diseases occurring in IBD vary from
subclinical abnormality of pulmonary function to
disease of large and small airways and parenchymal
involvement. As to the latter, the side effects of treat-
ment in the form of hypersensitivity reactions must
be taken into account [5].
MTX, an antagonist of folic acid, is the most com-
monly used drug in rheumatoid arthritis and since
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the end of 1980 it is also administered for its anti-
inflammatory activity in refractory IBD disease,
with the aim to improve symptoms and reduce
requirements for prednisone [6,7]. This drug is
responsible for numerous adverse reactions involv-
ing multiple organs, some of which life-threatening
like MTX-induced pneumonitis (MIP), which gener-
ally appears within the first year of treatment [8,9]
though a delay of 1-4 weeks after discontinuation of
the drug is also reported [10-12]. It may present as
acute, subacute or chronic [13]. The prevalence of
pneumonitis is reported to be 0.3-0.7% [14].
Imokawa et al. [15], in their review of the English
literature, show 123 cases of MIP, but none was
affected by IBD. To our knowledge, only one case of
MTX-related pneumonitis in a patient with Crohn's
disease has formerly been reported [16].
Here we report a second case of pneumonitis MTX-
induced in Crohn's disease.
Case report
A 44-year old woman was followed up by the
Gastroenterology Unit of our hospital since 1995
when Crohn's disease was diagnosed. She under-
went steroid treatment (more than two cycles/year
of prednisone 20 mg/day) without complete disease
remission. In 1998 she was admitted to hospital for
a moderate/severe relapse of IBD with appearance
of extraintestinal manifestations (peripheral arthritis,
sacroileitis and erythema nodosum). Thus, azathio-
prine (2.5 mg/kg/die) was added to a higher dose of
prednisone (1 mg/Kg/die) with rapid resolution of
symptoms, but this drug was discontinued after few
months owing to the onset of acute pancreatitis. At
that moment a maintenance treatment with
methotrexate was refused by the patient due to a
possible pregnancy, so a long-term strategy of
steroid tapering was applied (that ended in
November 1999). Between 1999 and 2001 some
light relapses were treated with salazopirine and
antibiotic therapy.
In 2003, because of a new relapse, an induction
regimen with anti tumor necrosis factor (TNF)-alfa
antibodies (infliximab 5 mg/kg at 0, 2 and 6 weeks)
was started, obtaining a complete clinical and
endoscopic remission. 
A maintenance therapy with oral methotrexate 15
mg once a week was started in April 2003, with
clinical and endoscopic remission until July 2005,
when, due to the onset of acute dyspnea, cough
without sputum production, fever and parossistic
supraventricular tachycardia, the patient was admit-
ted to the emergency ward of our general hospital.
At presentation the patient was tachypneic (22
breaths/min), tachycardic (140 bpm) and febrile
(38.5°C) and reported dyspnea during exercise for
at least two weeks. She did not smoke or suffer from
any pulmonary disease in the past. At physical
examination no cyanosis or other alterations were
evident, while at auscultation of the thorax bilateral
dry crackles in medium-low lung fields were found.
Laboratory studies showed an increase in inflam-
matory markers (C-reactive protein 2.8 mg/dl, nor-
mal value < 0.5 mg/dl; erythrocyte sedimentation
rate 56 mm/h) and in white blood cells count
(14,200 with 68% neutrophils and 6% eosinophils),
and a mild anemia was detected (hemoglobin 11.2
g/dl). Arterial blood gas analysis showed normox-
emia with respiratory alkalosis due to hyperventila-
tion: pH 7.47, PaCO2 29.3 mm Hg, PaO2 103.6 mm
Hg, BE -1.1 mmol/l). 
The chest radiograph showed diffuse bilateral retic-
ular infiltrates of the mid-lower zones of both lungs
with merging at the left base. A high-resolution
computed tomography (HRCT) of the thorax
showed a bilateral distribution of ground glass
opacities especially diffuse in the mid-upper zones
of the lung, sparing the peripheral fields, and with-
out distortion of pulmonary parenchyma (Figure
1a). Pulmonary function tests (PFTs) revealed an
obstructive mild defect, with severe reduction of the
diffusing lung capacity for carbon monoxide (DLCO)
(Figure 1b). The serological tests for the detection of
common respiratory viruses, Legionella pneumo -
phila, Mycoplasma pneumoniae and Rickettsia,
together with the autoantibodies assays (ANA, ENA,
ANCA), were negative (Table I). Bacterial and fungal
stains and culture of sputum were negative. On the
basis of clinical setting and radiological pattern an
acute interstitial lung disease caused by methotrex-
ate was suspected. Methotrexate was discontinued
and corticosteroids (prednisone 1 mg/kg) plus
antibiotic therapy (clarythromycin 1 gr/die) were
prescribed and the patient's illness resolved within
1 week of starting this therapy.
Four weeks later the HRCT showed no abnormali-
ties of the lung parenchyma (Figure 2a) and the
PFTs were normal (Figure 2b). After this episode
there was no further occurrence of respiratory
symptoms. At present, the patient is on stable remis-
sion with biological treatment (adalimumab) with-
out adverse effects.
FIGURE 1A: HRCT OF LUNG DURING METHOTREXATE
THERAPY
Diffuse bilateral alveolar infiltrates and ground glass areas can be
seen without distortion of pulmonary parenchyma.  

































Among extraintestinal manifestations (EIM) of
inflammatory bowel diseases (IBD) pulmonary
involvement has been described much less fre-
quently than other complications [1,2], ranging
from subclinical pulmonary function abnormalities
to interstitial fibrosis. However, Songur et al. [17]
reported that HRCT or pulmonary function abnor-
malities are present in a surprisingly large propor-
tion of IBD patients (53% and 58%, respectively)
and 42% of the patients with HRCT abnormalities
did not have respiratory symptoms. Some authors
reported pulmonary impairment in IBD patients to
be related to disease activity [18-20]: approximate-
ly 80% of the patients with pulmonary involvement
had active bowel disease [17], suggesting a direct
pathogenetic link to the IBD itself; however an
ongoing bowel inflammation is not a prerequisite for
the onset of respiratory alterations, since broncho-
pulmonary diseases that developed after colectomy
have been reported [21]. In all cases, drug-induced
pulmonary disease, a rare side effect of sulfalazina,
mesalamine and methotrexate, must be ruled out
[22]. 
Methotrexate, which has recently been shown to
have utility for long-term maintenance therapy in
Crohn’s disease, has been related to a pneumonitis
(methotrexate-induced pneumonitis, MIP) that can
become life threatening [23] and represent a serious
and far less predictable side-effect of treatment with
MTX [24]. 
As many as 60 to 93% of patients treated with
methotrexate eventually develop at least one
adverse reaction, most commonly involving the
skin, gastrointestinal tract, or central nervous system
[25,26]. Most of these reactions are not life-threat-
ening. Nevertheless, up to 30% of patients treated
for more than five years with MTX discontinue the
therapy because of unacceptable toxicity [27,28].
Major and potentially life-threatening toxicities
affect lung [29,30], liver [31], and the hematopoiet-
ic system [32]. Most series estimate that pulmonary
toxicity develops in 2 to 7% of patients receiving
methotrexate [33,34], but some reports suggest an

























FIGURE 1B: PFT AT ADMISSION TO HOSPITAL
Mild obstructive defect with severe reduction of DLCO
Definition of abbreviations: DLCO, diffusing lung capacity for carbon
monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity; PFT, pulmonary function test; TLC, total lung capacity;
VC, vital capacity.
TABLE I: SEROLOGICAL TESTS    
Serodiagnosis for Listeria
Anti-Listeria H   I    serotype Negative Negative < 160
Anti-Listeria H   4b serotype Negative Negative < 160
Anti-Listeria O   I    serotype Negative Negative < 160
Anti-Listeria O   4b serotype Negative Negative < 160
Serodiagnosis for most common pneumotropic pathogens
Legionella pneumophila IgM Absent
Mycoplasma pneumoniae IgM Absent
Coxiella burnetii IgM Absent
Chlamydia pneumoniae IgM Absent
Adenovirus IgM Absent
Respiratory syncytial virus IgM Absent
Influenza A virus IgM Absent
Influenza B virus IgM Absent
Parainfluenza 1, 2, 3 virus IgM Absent
Cytomegalovirus Ab
Cytomegalovirus IgG 599 UA/ml Negative < 15

















ity has been well-described and MIP is the most
common complication associated with the use of
methotrexate [36-38], but a variety of other pul-
monary conditions have been associated with the
use of this drug, including bronchiolitis obliterans
with organizing pneumonia [29], acute lung injury
with noncardiogenic pulmonary edema [39], pul-
monary fibrosis (which may be rapidly progressive),
bronchitis with airways hyperreactivity [39], and
isolated pleuritis [40]. The occurrence of MIP has
mainly been reported in patients affected by
rheumatoid arthritis [15] and to our knowledge only
one other case of pulmonary toxicity has been
described in a patient affected with IBD. Thus, this
is the second case of MIP occurring in the course of
IBD [16]. 
Surprisingly, the two cases were very similar; in
both cases the patients were relatively young
women, both affected by Crohn's disease and with
steroid-dependent disease.
There is no single pathognomonic test for
methotrexate pulmonary toxicity, and a clinico-
pathological correlation is required for each indi-
vidual case [41]. The diagnosis might be difficult
and it is mainly a diagnosis of exclusion: in fact it is
imperative to rule out the possibility of pulmonary
infection and other respiratory diseases before diag-
nosing and treating methotrexate-induced lung
alterations [14,42]. 
Four different groups have proposed similar criteria,
specifically based on anamnestic data and clinical
manifestations, radiographic abnormalities, bron-
choalveolar lavage, and lung histology in a minority
of cases, for the diagnosis of MTX lung injury [43-
46] (Table III).
The proposed multiparametric scoring systems have
not been adequately validated and their sensitivity
has not been studied [23]; however, the clinical set-
ting together with some radiological findings are
useful for formulating the diagnosis [14] as in the
present case.
Interstitial opacities or mixed interstitial and alveo-
lar infiltration can be demonstrated at the chest X-
ray, but this can also be normal in a minority of
cases [15]. HRCT is superior to plain chest radi-
ographs for demonstrating and characterizing the
MTX-induced toxicity [47], and it can show patchy
areas of ground glass attenuation with small areas
of consolidation [48], i.e. precisely the pattern we
observed in our patient. 
Pulmonary function tests in methotrexate pneu-
monitis generally reveal a volume decrease, espe-
cially of vital capacity (VC), and a reduction of car-
bon monoxide diffusing capacity (DLCO), [36,37]
even if these features are suggestive of but not spe-
cific for MIP [49]. Nevertheless, the majority of
patients submitted to long term methotrexate thera-
py show no deterioration in pulmonary function
[50-52], and in few cases was worsening of airflow
obstruction noted, although it is unclear to what
degree methotrexate was responsible for these alter-
ations [49,53].
Pulmonary histology can be helpful in making the
differential diagnosis from other causes, but the
findings are not specific or diagnostic for any MTX-
FIGURE 2A: HRCT OF LUNG AFTER DISCONTINUATION OF
METHOTREXATE THERAPY
No lung abnormalities can be observed.


























FIGURE 2B: PFT AT OUTCOME
Normalization of functional parameters. 
Definition of abbreviations: DLCO, diffusing lung capacity for carbon
monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced
































induced pulmonary disease, whereas bronchoalve-
olar lavage (BAL) is helpful to rule out an infectious
etiology [54]. 
Evidence in support of the diagnosis of pulmonary
toxicity from methotrexate results from clinical
improvement after discontinuation of the drug
and/or the response to corticosteroid treatment.
A subacute illness is the commonest modality of
presentation of methotrexate pulmonary toxicity
[14,55]. The majority of patients who develop
methotrexate pulmonary toxicity do so within the
first year of therapy [42], but cases with an onset as
early as 12 days after have been reported [15], and
pulmonary complications may appear even some
weeks after discontinuation of treatment [56,57] or
after a longer period of drug administration. In fact,
in the case presented here the respiratory symptoms
began late with insidious dyspnea during exercise
and progressed until an acute increase in symptoms
with fever, dry cough, tachypnea and tachycardia
forced the patient to seek hospital admission, while
MTX therapy had been started more than two years
before. We do not know the precise reason why
methotrexate pulmonary toxicity did manifest such
a long time after the beginning of treatment; certain-
ly it was not related to an exacerbation of the chron-
ic intestinal disease that was well controlled at that
time. 
Subacute pneumonitis manifests with dyspnea, non
productive cough, fever, and crackles with tachy -
pnea on physical examination [15]. A progression
to pulmonary fibrosis is observed in approximately
10% of patients [29]. The clinical presentation of
acute methotrexate pneumonitis is generally unspe-
cific with fever, chills, cough, dyspnea, chest pain
and fatigue [46,58-61] and it has been observed in
2 to 5% of patients treated for rheumatoid arthritis
[38,59-61]. 
The prognosis of MTX pneumonitis is not entirely
benign [14,36] and rapid progression to respiratory
failure may also occur [36,37].
No prospective trials concerning the therapy for
MTX-induced pneumonitis have been performed.
Imokawa et al. [15] in their review of 123 cases of
MIP (none affected by IBD) reported 26% of cases
treated with discontinuation of MTX only, 53% with
discontinuation associated to administration of cor-
ticosteroids and 21% treated with other non-
explained therapies. Mortality was 15.8%, and in
76% of these cases due to respiratory disease. In
their own case series of 9 MIP, MTX was stopped in
all cases, corticosteroid therapy was started in 8,
and 2 patients died because of respiratory failure.
Although there is no established protocol, the ther-
apy is generally started with 1 mg/kg per day of
methylprednisolone or equivalents, initially intra-
venous in severely ill patients, and tapered over the
subsequent 2 or 4 weeks [62].
The value of corticosteroids in methotrexate pul-
monary toxicity has not been examined in large-
sized trials [35] but such trials likely would be
unnecessary due to the proven efficacy of cortico -
steroids in a life threatening disease [36]. The prog-
nosis is substantially good, although some abnor-
malities of respiratory function could remain, while
about a 1% mortality rate is calculated [36,63].
Empiric antimicrobial therapy directed at likely
pathogens may be indicated while definitive proced -
ures and cultures are performed. As occurred in our
patient, clinical improvement usually occurs within
some days of stopping the drug, followed by
improvement in the chest radiograph over several
weeks [45]. While there are reports of successful
rechallenge with methotrexate and even regression
of pulmonary toxicity despite continued therapy,
these approaches are not recommended [44,64]
since they may induce a relapse of MIP or death
[24]. 
In our specific clinical setting, the diagnosis of
MTX-induced pneumonitis is based on the set of
criteria proposed by Alarcón et al. [43] (Table II), of
which two major criteria and three minor criteria
were encountered in our patient. In Alarcón et al.'s
study [43] older age represents the strongest predic-
tor of lung injury, the risk being double in 50-59
year-old patients and six-fold in patients over 60
TABLE II: CRITERIA FOR DEFINITE OR PROBABLE METHOTREXATE PNEUMONITIS DIAGNOSIS    
Methotrexate pneumonitis is characterized as "definite" if one of the major criteria is present in conjunction with three of the five minor
criteria. "Probable" methotrexate pneumonitis is present if major criteria 2 and 3 plus two of the five minor criteria are present [43]*.
Major criteria
• Hypersensitivity pneumonitis by histopathology without evidence of pathogenic organisms
• Radiologic evidence of pulmonary interstitial or alveolar infiltrates
• Blood cultures (if febrile) and initial sputum cultures (if sputum is produced) that are negative for pathogenic organisms.
Minor criteria
• Shortness of breath for less than eight weeks
• Nonproductive cough
• Oxygen saturation ≤ 90% on room air at the time of initial evaluation
• DLCO ≤70% of predicted for age
• Leukocyte count ≤ 15,000 cells/mm3.

















years old. As regards the risk factors indicated by
Alarcón et al., neither older age, nor diabetes nor
hypoalbuminemia were present, and no pre-exist-
ing pulmonary diseases appeared in the anamnestic
evaluation of our non smoking patient, as supposed
by Searles [45]. Only a mild chronic anaemia was
present to debilitate our patient.
The pathogenesis of MTX lung toxicity is uncertain.
The two most suggestive theories are: an acute
hypersensitivity reaction or a direct cytotoxic action
[64]. The first is supported by the evidence in a few
cases of eosinophilia and release of lymphokine,
leucocyte inhibitor factor from peripheral blood
lymphocytes [65] and a dramatic response to corti-
costeroids.
The second is supported by the fact that MTX accu-
mulates preferentially in the lung [66] and a clinical
resolution may follow the stop of MTX without
administration of corticosteroids.
In our patient the presence of eosinophilia, and the
prompt improvement in symptoms and in radio -
graphic alterations observed after corticosteroid
therapy, make us certain of a possible immune-
mediated phenomenon. 
The time of MIP presentation is unpredictable; in
our patient it appeared when she had been under-
going methotrexate treatment for 25 months.
Hence, as MIP is a potentially fatal disease, a
prompt evaluation of any new respiratory symptoms
in patients treated with MTX is imperative. In fact,
early diagnosis of possible alterations, even moni-
toring pulmonary function tests [67], may reduce
severe morbidity and mortality.
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